Belimumab in Remission of VASculitis (BREVAS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01663623

Recruitment Status : Completed

First Posted : August 13, 2012

Results First Posted : April 17, 2018

Last Update Posted : April 17, 2018

Sponsor:

Collaborator:

GlaxoSmithKline

Information provided by (Responsible Party):

GlaxoSmithKline ( Human Genome Sciences Inc., a GSK Company )

Study Description

Brief Summary:

The purpose of this study is to evaluate the efficacy and safety of belimumab, in combination with azathioprine, for the maintenance of remission following a standard induction regimen in patients with Wegener's granulomatosis or microscopic polyangiitis. The random assignment in this study is "1 to 1" which means that participants have an equal chance of receiving belimumab or placebo.

Condition or disease	Intervention/treatment	Phase
Vasculitis	Biological: Placebo Biological: Belimumab 10 mg/kg Drug: Azathioprine	Phase 3

Study Design


Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	106 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:	Treatment
Official Title:	A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis
Actual Study Start Date :	March 20, 2013
Actual Primary Completion Date :	February 6, 2017
Actual Study Completion Date :	February 6, 2017

Resource links provided by the National Library of Medicine

Genetics Home Reference related topics: Granulomatosis with polyangiitis

MedlinePlus related topics: Granulomatosis with Polyangiitis Vasculitis

Drug Information available for: Azathioprine Azathioprine Sodium Belimumab

Genetic and Rare Diseases Information Center resources: Granulomatosis With Polyangiitis Microscopic Polyangiitis ANCA-associated Vasculitis

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Placebo Comparator: Placebo plus azathioprine Placebo IV plus oral azathioprine 2 mg/kg/day; placebo administered on Days 0, 14, 28, and then every 28 days until the end of the study. If the results in the double-blind period show that belimumab is safe and effective, then participants have the option to receive treatment with belimumab in a 6-month open-label extension phase. Placebo patients who opt to participate in the extension will receive belimumab 10 mg/kg IV every 28 days plus oral azathioprine 2 mg/kg/day for an additional 6 months.	Biological: Placebo Placebo Drug: Azathioprine Azathioprine
Experimental: Belimumab 10 mg/kg plus azathioprine Belimumab 10 mg/kg IV plus oral azathioprine 2 mg/kg/day; belimumab administered on Days 0, 14, 28, and then every 28 days until the end of the study. If the results in the double-blind period show that belimumab is safe and effective, then participants have the option to continue treatment with belimumab in a 6-month open-label extension phase. Patients who opt to participate in the extension will continue to receive belimumab 10 mg/kg IV every 28 plus oral azathioprine 2 mg/kg/day days for an additional 6 months.	Biological: Belimumab 10 mg/kg Belimumab 10 mg/kg Other Name: BENLYSTA™ Drug: Azathioprine Azathioprine

Arm

Intervention/treatment

Placebo Comparator: Placebo plus azathioprine

Placebo IV plus oral azathioprine 2 mg/kg/day; placebo administered on Days 0, 14, 28, and then every 28 days until the end of the study. If the results in the double-blind period show that belimumab is safe and effective, then participants have the option to receive treatment with belimumab in a 6-month open-label extension phase. Placebo patients who opt to participate in the extension will receive belimumab 10 mg/kg IV every 28 days plus oral azathioprine 2 mg/kg/day for an additional 6 months.

Biological: Placebo

Placebo

Drug: Azathioprine

Azathioprine

Experimental: Belimumab 10 mg/kg plus azathioprine

Belimumab 10 mg/kg IV plus oral azathioprine 2 mg/kg/day; belimumab administered on Days 0, 14, 28, and then every 28 days until the end of the study. If the results in the double-blind period show that belimumab is safe and effective, then participants have the option to continue treatment with belimumab in a 6-month open-label extension phase. Patients who opt to participate in the extension will continue to receive belimumab 10 mg/kg IV every 28 plus oral azathioprine 2 mg/kg/day days for an additional 6 months.

Biological: Belimumab 10 mg/kg

Belimumab 10 mg/kg

Other Name: BENLYSTA™

Drug: Azathioprine

Azathioprine

Outcome Measures

Primary Outcome Measures :

Time to First Relapse [ Time Frame: Approximately up to 4 years ]
Time to relapse is defined as the number of days from Day 0 until the participant experienced a relapse (relapse date - treatment start date +1). Only post-baseline relapses were considered in these analyses. Only relapses occurring up to and including the last visit date in the double-blind treatment period were considered in these analyses. Intent-to-treat population comprised of all randomized participants who received at least one dose of study agent (belimumab or placebo). NA indicates that the data was not available as the Number of events is too low to estimate the value. Median and Inter-quartile range were presented and were based on Kaplan Meier estimates.

Secondary Outcome Measures :

Number of Participants With Major Relapse During the Double-blind Phase of the Study [ Time Frame: Approximately up to 4 years ]
Data for number of participants with major relapse [defined as experiencing at least 1 major Birmingham Vasculitis Activity Score (BVAS) item] during the double-bind phase of the study was reported. Analysis was performed using a Cox proportional hazard model.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Key Inclusion Criteria:

Clinical diagnosis Wegener's granulomatosis or microscopic polyangiitis by Chapel Hill criteria.
Disease flare in the past 26 weeks requiring treatment with high dose corticosteroids and 1 of the following medications: rituximab, oral cyclophosphamide OR IV cyclophosphamide.
Tested positive for anti-proteinase 3 (anti-PR3) or anti-myeloperoxidase (anti-MPO) antibodies at any time prior to enrollment.
Achieve remission no more than 26 weeks after first dose of induction treatment. Remission is defined as a Birmingham Vasculitis Activity (BVAS) score of 0 and receiving less than 10 mg/day of oral prednisone (or equivalent) on 2 consecutive visits 21 to 35 days apart.
Maintenance therapy on this study must start no more than 2 weeks after confirmation of remission.

Key Exclusion Criteria:

Pregnant or nursing.
Receipt of a B cell targeted therapy (other than rituximab) at anytime
Receipt of an investigational biological agent within the past 60 days.
Required management of acute or chronic infections within the past 60 days.
Current drug or alcohol abuse or dependence.
Current or past positive test for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.
History of severe allergic reaction to contrast agents or biological medicines.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01663623

Show 89 Study Locations

Sponsors and Collaborators

Human Genome Sciences Inc., a GSK Company

GlaxoSmithKline

Investigators


Study Director:	GSK Clinical Trials	GlaxoSmithKline

Study Documents (Full-Text)

Documents provided by GlaxoSmithKline ( Human Genome Sciences Inc., a GSK Company ):

Study Protocol [PDF] February 26, 2015

Statistical Analysis Plan [PDF] March 6, 2017

More Information


Responsible Party:	Human Genome Sciences Inc., a GSK Company
ClinicalTrials.gov Identifier:	NCT01663623 History of Changes
Other Study ID Numbers:	115466
First Posted:	August 13, 2012 Key Record Dates
Results First Posted:	April 17, 2018
Last Update Posted:	April 17, 2018
Last Verified:	March 2018


Studies a U.S. FDA-regulated Drug Product:		Yes
Studies a U.S. FDA-regulated Device Product:		No

Keywords provided by GlaxoSmithKline ( Human Genome Sciences Inc., a GSK Company ):


Wegener's Granulomatosis anti-MPO WG Belimumab GPA anti-proteinase 3 anti-neutrophil cytoplasmic antibody anti-myeloperoxidase	Granulomatosis with polyangiitis Vasculitis Autoimmune Diseases Microscopic Polyangiitis anti-PR3 ANCA MPA Systemic Vasculitis

Additional relevant MeSH terms:


Vasculitis Granulomatosis with Polyangiitis Microscopic Polyangiitis Vascular Diseases Cardiovascular Diseases Lung Diseases, Interstitial Lung Diseases Respiratory Tract Diseases Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Systemic Vasculitis Autoimmune Diseases Immune System Diseases Cerebral Small Vessel Diseases Cerebrovascular Disorders	Brain Diseases Central Nervous System Diseases Nervous System Diseases Azathioprine Belimumab Antimetabolites Molecular Mechanisms of Pharmacological Action Antimetabolites, Antineoplastic Antineoplastic Agents Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents

To Top